Research progress in immunotherapy of advanced non-small cell lung cancer

Non-small cell lung cancer (NSCLC) poses a serious threat to people’s health. Its morbidity and mortality are among the highest all malignant tumors, there is an urgent need for more effective new treatment methods. In recent years, NSCLC immunotherapy has made great progress, first PD-1 inhibitor nivolumab (Nivolumab, O drug) was approved by US Food Drug Administration (FDA) in March 2015, applying patients who progressed or received platinum chemotherapy drugs past. Immunotherapy of advanced entered era. This article reviews current research progress immunotherapy.